Three others – for opioid withdrawal, insomnia/narcolepsy, cerebral ischaemia, migraine, and trigeminal neuralgia – are due to be put to the vote as the meeting continues today. Kennedy overhauled the roster of the PCAC ahead of the adcomm meeting, adding new members with ties to the peptide industry, including some who own clinics that offer them to patients. Kennedy has called himself a "big fan" of compounded peptides and has pledged to ease restrictions on them introduced under the Biden administration, which banned pharmacies from producing 19 formulations in 2023 due to safety concerns. While the FDA could go against the advice of its adcomm and keep the bans in place, there is already speculation that Kennedy might overrule that decision. A non-profit patient safety organisation, the Institute for Safe Medication Practices (ISMP), said that the commercial market for compounded peptides has grown far more quickly than the science.